tetano
Editor, Senior Moderator
accine X. 2019 Jun 20;2:100029. doi: 10.1016/j.jvacx.2019.100029. eCollection 2019 Aug 9. [h=1]No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination.[/h] Madsen A[SUP]1[/SUP], Azimi L[SUP]1[/SUP], Tete S[SUP]1,[/SUP][SUP]2[/SUP], Zhou F[SUP]1,[/SUP][SUP]2[/SUP], Krammer F[SUP]3[/SUP], Cox RJ[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], Jul-Larsen ?[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h] 1 Influenza Centre, Department of Clinical Science, University of Bergen, Norway. 2 K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Norway. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4 Department of Research and Development, Haukeland University Hospital, Bergen, Norway.
[h=3]Abstract[/h] Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual's previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009. We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza.
[h=4]KEYWORDS:[/h] AS03; Antigenic seniority; Healthcare worker; Pandemic vaccine
PMID: 31384744 PMCID: PMC6668305 DOI: 10.1016/j.jvacx.2019.100029
Free PMC Article
[h=3]Author information[/h] 1 Influenza Centre, Department of Clinical Science, University of Bergen, Norway. 2 K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Norway. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4 Department of Research and Development, Haukeland University Hospital, Bergen, Norway.
[h=3]Abstract[/h] Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual's previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009. We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza.
[h=4]KEYWORDS:[/h] AS03; Antigenic seniority; Healthcare worker; Pandemic vaccine
PMID: 31384744 PMCID: PMC6668305 DOI: 10.1016/j.jvacx.2019.100029
Free PMC Article